Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment. LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy…